Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03752203 · ClinicalTrials.gov registry record · NA
Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors
A NA study, sponsored by University of Colorado, Denver.
- Terminated
- Registry status
- NA
- Development phase
- 2
- Enrollment target
NCT03752203: Clinical Trial NA study, sponsored by University of Colorado, Denver.
NCT03752203 is a NA study that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 2 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03752203, a NA study, was terminated before completion, sponsored by University of Colorado, Denver.
- TERMINATED
- Registry status
- NA
- Development phase
- 2 participants
- Enrollment target
Study Summary
Sodium fluorescein, which has been shown to be useful for intraoperative guidance regarding the resection of adult neurosurgical tumors, can aid the resection of pediatric neurosurgical tumors.
Primary Outcome
For all patients, pre-operative imaging and post-operative imaging will be used to analyze the extent of resection of the tumors. In intracranial lesions, the use of volumetric imaging tools will be used to calculate the extent of tumor resection.
Interventions
- DRUG Sodium Fluorescein
- DEVICE Microscopic Resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2021-08-11 |
| Est. Completion | 2023-06-29 |
| Phase | NA |
Why NCT03752203 stopped before completion
NCT03752203 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Sodium Fluorescein is the first listed.
NCT03752203 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03752203 about?
NCT03752203 is a clinical study titled "Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors". Sodium fluorescein, which has been shown to be useful for intraoperative guidance regarding the resection of adult neurosurgical tumors, can aid the resection of pediatric neurosurgical tumors.
What is the current status of trial NCT03752203?
This trial is currently terminated. It is a NA study. The enrollment target is 2 participants. The study started on 2021-08-11. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT03752203?
The interventions under investigation include: Sodium Fluorescein (DRUG), Microscopic Resection (DEVICE).
Who is sponsoring clinical trial NCT03752203?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03752203's enrollment target sits among peer trials
2 1997th of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI